drugset / Trial / NCT05473624

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

NCT05473624

Phase 1 Recruiting 153 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Timeline

Start
2022-08-23
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-1167 Unknown

Indications